Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA
NEW YORK and LONDON, Nov. 10, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the U.S. Food and Drug Administration (FDA) has granted the Rare Pediatric Disease Designation to nomacopan for the treatment of pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Rare Pediatric Disease Designation is an important addition to the Orphan Drug and Fast Track designations previously granted by the FDA for nomacopan in pediatric HSCT-TMA.
Related news for (AKTX)
- Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
- Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
- Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification